Immucell Corp (ICCC) Stock Price, Quote & News

Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronaviru...

Industry: Biotechnology

Sector: Healthcare

Phone: 207 878 2770

Website: immucell.com

Address:

56 Evergreen Drive, Portland, United States

TommyTwenty May. 11 at 4:21 PM

$ICCC https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-a52db580f93f.html

0 · Reply

theRooster007 Apr. 30 at 11:56 PM

$ICCC

0 · Reply

TommyTwenty Apr. 30 at 8:40 PM

$ICCC The test launch for Retain began in December so I think the data is coming relatively soon atleast. Data will be used to seek a “partner.” Is that you, finish line?

0 · Reply

theRooster007 Apr. 29 at 4:28 PM

$ICCC 🥛

0 · Reply

theRooster007 Apr. 22 at 4:49 PM

$ICCC https://www.zacks.com/stock/news/2905060/the-zacks-analyst-blog-the-goldman-sachs-nextera-shopify-landmark-and-immucell

0 · Reply

theRooster007 Apr. 20 at 9:47 PM

$ICCC both on newest ceo and newest board member of the strategy and tech committee dr. Gilles guilmette resumes.....🤔

0 · Reply

theRooster007 Apr. 20 at 1:56 PM

$ICCC blue skies at $11

1 · Reply

theRooster007 Apr. 16 at 3:24 PM

$ICCC pe firm archimeds largest global animal health company Ceva can do manufacturing. Current ceo and newest leader of strategy committee linked to archimed.

0 · Reply

TommyTwenty Apr. 16 at 2:42 AM

$ICCC

0 · Reply

OfficialStocktwitsUser Apr. 15 at 6:08 PM

$ICCC RSI: 75.00, MACD: 0.2625 Vol: 0.48, MA20: 6.62, MA50: 6.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

Apr 13, 2026, 4:38 PM EDT - 4 weeks ago

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

Apr 8, 2026, 4:05 PM EDT - 4 weeks ago

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

Mar 18, 2026, 4:05 PM EDT - 7 weeks ago

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

Mar 5, 2026, 9:00 AM EST - 2 months ago

ImmuCell Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:05 PM EST - 2 months ago

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

Feb 18, 2026, 8:37 AM EST - 3 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

Jan 9, 2026, 9:00 AM EST - 4 months ago

ImmuCell Earnings Call Transcript: Q4 2025

2026-01-08T21:20:53.000Z - 4 months ago

Immucell reports preliminary Q4 revenue $7.6M

Jan 8, 2026, 4:05 PM EST - 4 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

Jan 7, 2026, 8:10 AM EST - 4 months ago

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

2025-12-24T18:10:09.000Z - 5 months ago

Immucell to pause further investment in Re-Tain after FDA Incomplete Letter

Dec 24, 2025, 1:05 PM EST - 5 months ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

Nov 14, 2025, 9:00 AM EST - 6 months ago

ImmuCell Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 4, 2025, 4:05 PM EST - 6 months ago

ImmuCell Announces Onboarding of New CEO and Related Management Changes

2025-10-07T20:15:30.000Z - 7 months ago

Immucell reports preliminary Q3 revenue $5.5M vs. $6M last year

Oct 7, 2025, 4:05 PM EDT - 7 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

Sep 30, 2025, 4:15 PM EDT - 8 months ago

ImmuCell Transcript: Lytham Partners Fall 2025 Investor Conference

2025-09-29T20:16:22.000Z - 8 months ago

Immucell appoints Olivier te Boekhorst CEO

Sep 29, 2025, 4:05 PM EDT - 8 months ago

ImmuCell Announces Selection of its Next President and CEO

Aug 15, 2025, 9:00 AM EDT - 9 months ago

ImmuCell Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

Aug 12, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Bank Debt Refinancing

Aug 7, 2025, 8:00 AM EDT - 9 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

2025-07-09T12:10:10.000Z - 11 months ago

Immucell reports preliminary unaudited Q1 revenue $6.4M vs. $5.5M last year

Jul 9, 2025, 8:00 AM EDT - 11 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

2025-06-25T14:40:24.000Z - 11 months ago

ImmuCell trading resumes

2025-06-25T14:30:30.000Z - 11 months ago

ImmuCell trading halted, volatility trading pause

2025-06-25T12:16:11.000Z - 11 months ago

Immucell embarks on CEO succession planning process

Jun 25, 2025, 8:00 AM EDT - 11 months ago

ImmuCell Embarks on CEO Succession Planning Process

2025-06-20T18:30:12.000Z - 11 months ago

ImmuCell trading resumes

2025-06-20T18:25:25.000Z - 11 months ago

ImmuCell trading halted, volatility trading pause

Jun 5, 2025, 6:30 AM EDT - 1 year ago

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

May 29, 2025, 9:30 AM EDT - 1 year ago

ImmuCell Transcript: Lytham Partners Spring 2025 Investor Conference

May 15, 2025, 9:00 AM EDT - 1 year ago

ImmuCell Earnings Call Transcript: Q1 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

May 12, 2025, 8:42 AM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

2025-04-08T20:26:05.000Z - 1 year ago

Immucell reports preliminary Q1 revenue $8.1M vs. $7.3M last year

Apr 8, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

2025-04-07T13:07:50.000Z - 1 year ago

Immucell appoints Timothy Fiori as CFO

2025-04-02T20:15:56.000Z - 1 year ago

Immucell initiates Investigational Product use of Re-Tain

Apr 2, 2025, 4:05 PM EDT - 1 year ago

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Apr 1, 2025, 4:00 PM EDT - 1 year ago

ImmuCell Transcript: Lytham Partners 2025 Industrials & Basic Materials Investor Summit

Feb 26, 2025, 9:00 AM EST - 1 year ago

ImmuCell Earnings Call Transcript: Q4 2024

2025-02-25T21:55:18.000Z - 1 year ago

Immucell sees FY25 revenue $111M-$113M, consensus $107.93M

Feb 25, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Feb 20, 2025, 8:19 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

2025-01-16T21:15:57.000Z - 1 year ago

Immucell settles contamination insurance claim, to pay additional $426,587

Jan 16, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

2025-01-09T21:10:44.000Z - 1 year ago

Immucell reports preliminary Q4 sales $7.8M vs. $5.1M last year

Jan 9, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

Nov 14, 2024, 9:00 AM EST - 1 year ago

ImmuCell Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

2024-10-08T20:15:09.000Z - 1 year ago

Immucell reports Q3 revenue $6M, one estimate $5.4M

Oct 8, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

Aug 14, 2024, 9:00 AM EDT - 1 year ago

ImmuCell Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

2024-07-09T20:11:18.000Z - 2 years ago

Immucell reports preliminary Q2 revenue $5.47, one estimate $5.4M

Jul 9, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

2024-06-05T20:17:29.000Z - 2 years ago

Immucell updates status of product development initiative for Re-Tain

Jun 5, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

May 15, 2024, 9:00 AM EDT - 2 years ago

ImmuCell Earnings Call Transcript: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

May 8, 2024, 1:00 PM EDT - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

Apr 9, 2024, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

2024-04-01T21:16:52.000Z - 2 years ago

Immucell files $20M mixed securities shelf

Feb 28, 2024, 9:00 AM EST - 2 years ago

ImmuCell Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Feb 16, 2024, 9:30 AM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Jan 8, 2024, 4:05 PM EST - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

Nov 14, 2023, 9:00 AM EST - 2 years ago

ImmuCell Earnings Call Transcript: Q3 2023

Nov 13, 2023, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Nov 7, 2023, 12:15 PM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Oct 5, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

Aug 29, 2023, 8:00 AM EDT - 2 years ago

ImmuCell Announces Submission of CMC Technical Section to the FDA

Aug 11, 2023, 9:00 AM EDT - 2 years ago

ImmuCell Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

Aug 7, 2023, 12:00 PM EDT - 3 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Jul 11, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

Jun 28, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Announces Change in Timing of Anticipated FDA Submission

Jun 21, 2023, 4:05 PM EDT - 3 years ago

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

TommyTwenty May. 11 at 4:21 PM

$ICCC https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-a52db580f93f.html

0 · Reply

theRooster007 Apr. 30 at 11:56 PM

$ICCC

0 · Reply

TommyTwenty Apr. 30 at 8:40 PM

$ICCC The test launch for Retain began in December so I think the data is coming relatively soon atleast. Data will be used to seek a “partner.” Is that you, finish line?

0 · Reply

theRooster007 Apr. 29 at 4:28 PM

$ICCC 🥛

0 · Reply

theRooster007 Apr. 22 at 4:49 PM

$ICCC https://www.zacks.com/stock/news/2905060/the-zacks-analyst-blog-the-goldman-sachs-nextera-shopify-landmark-and-immucell

0 · Reply

theRooster007 Apr. 20 at 9:47 PM

$ICCC both on newest ceo and newest board member of the strategy and tech committee dr. Gilles guilmette resumes.....🤔

0 · Reply

theRooster007 Apr. 20 at 1:56 PM

$ICCC blue skies at $11

1 · Reply

theRooster007 Apr. 16 at 3:24 PM

$ICCC pe firm archimeds largest global animal health company Ceva can do manufacturing. Current ceo and newest leader of strategy committee linked to archimed.

0 · Reply

TommyTwenty Apr. 16 at 2:42 AM

$ICCC

0 · Reply

OfficialStocktwitsUser Apr. 15 at 6:08 PM

0 · Reply

focafoca99 Apr. 14 at 7:37 PM

$ICCC disclosed a board refresh with three directors stepping off and two new directors joining effective April 15.

0 · Reply

TommyTwenty Apr. 14 at 6:04 PM

$ICCC 1 new executive that comes from the same private equity firm as the new ceo. 1 new executive with a history of animal health M&A. They’re reducing the board to 7 after just reporting 28% sales increase. 6 independent directors and the ceo. The pop today on volume feels like buyout speculation.

0 · Reply

focafoca99 Apr. 13 at 10:01 PM

$ICCC added Gilles Guillemette and Anthony DiMarco to the board, reduced the board to seven seats and created a new Strategy and Technology Committee.

0 · Reply

theRooster007 Apr. 13 at 8:52 PM

$ICCC https://www.stocktitan.net/news/ICCC/immu-cell-bolsters-its-innovation-strategy-with-appointments-of-dr-6ru4bnelyvav.html

1 · Reply

focafoca99 Apr. 8 at 10:20 PM

$ICCC reported preliminary first-quarter sales of $10.4 million, up 28.4%, driven mainly by stronger Tri-Shield demand.

0 · Reply

Glopolon Apr. 8 at 8:28 PM

$ICCC Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. Great quarter, not sure, but probably first over $10M revenue

0 · Reply

TommyTwenty Apr. 8 at 8:25 PM

$ICCC https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-731452f7ef2f.html

0 · Reply

theRooster007 Apr. 1 at 3:57 AM

$ICCC data is coming https://archive.fast-edgar.com/20260330/AEZZB22CZC22R2Z2222P2WZZN7LMZ6T86U82/

0 · Reply

BillionerOfKing Mar. 7 at 12:57 AM

$ICCC Current Stock Price: $6.57

0 · Reply

ZacksResearch Mar. 6 at 7:02 PM

$ICCC tightening the ship? Net loss narrows as sales and margins move higher. 📈 2025 sales rose 4.3% year over year, and gross margin expanded sharply — helping shrink the company’s annual net loss even with asset write-downs and ongoing strategic shifts. See what’s driving the improvement 👉 https://www.zacks.com/stock/news/2880426/immucell-2025-net-loss-narrows-yy-as-sales-margins-improve?cid=sm-stocktwits-2-2880426-teaser-36434&ADID=SYND_STOCKTWITS_TWEET_2_2880426_TEASER_36434

0 · Reply

ZacksResearch Mar. 6 at 6:02 PM

$ICCC's 2025: Operational wins, but what's next? 📈 Product sales up 4.3% in 2025 compared to 2024, with net loss narrowing significantly. 🔧 Gross margin jumps to 41.4% from 30% due to improved production and manufacturing efficiencies. 📉 Q4 sales dip 1.6%, but domestic sales shine with an 8.7% increase. See what strategic shifts mean for ICCC's future 👉 https://www.zacks.com/stock/news/2880426/immucell-2025-net-loss-narrows-yy-as-sales-margins-improve?cid=sm-stocktwits-2-2880426-body-36435&ADID=SYND_STOCKTWITS_TWEET_2_2880426_BODY_36435

0 · Reply

StocktwitsEarnings Mar. 5 at 12:00 PM

$ICCC Q4 '25 Earnings Results & Recap Immucell reported 2025 product sales increased 4.3% to $27.6M, with gross profit improving to 41.4% from 30%. Net operating income reached $1.6M, an increase of $3.3M.

0 · Reply

Market Cap	76.45M
Revenue (ttm)	27.64M
Net Income (ttm)	-1.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.76%
Debt to Equity Ratio	0.34

Volume	16,444
Avg Vol	21,356
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	37%
Beta	0.50
Analysts	Strong Buy
Price Target	$14.00